Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions

被引：3
|
作者：
Hennessee, Ian [1 ,2 ]
Benedict, Kaitlin [1 ]
Bahr, Nathan C. [3 ]
Lipner, Shari R. [4 ]
Gold, Jeremy A. W. [4 ]
机构：
[1] CDCP, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop H24-11, Atlanta, GA 30329 USA
[2] CDCP, Epidem Intelligence Serv, Atlanta, GA USA
[3] Univ Kansas, Med Ctr, Dept Med, Div Infect Dis, Kansas City, KS USA
[4] Weill Cornell Med, Dept Dermatol, New York, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 03期
基金：
美国国家卫生研究院;
关键词：
biologics; candidiasis; coccidioidomycosis; corticosteroids; esophageal candidiasis; hidradenitis suppurativa; histoplasmosis; invasive fungal infections; psoriasis; pyoderma gangrenosum; seborrheic dermatitis; Stevens-Johnson syndrome; TNF-alpha inhibitors;
D O I：
10.1016/j.jaad.2024.03.046
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：510 / 513
页数：4
相关论文
共 50 条
  • [41] Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
    Kojima, Toshihisa
    Takahashi, Nobunori
    Funahashi, Koji
    Asai, Shuji
    Takemoto, Toki
    Asai, Nobuyuki
    Watanabe, Tatsuo
    Ishiguro, Naoki
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [42] Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients
    Kojima, Toshihisa
    Takahashi, Nobunori
    Kaneko, Atsushi
    Kida, Daihei
    Hirano, Yuji
    Fujibayashi, Takayoshi
    Yabe, Yuichiro
    Takagi, Hideki
    Oguchi, Takeshi
    Miyake, Hiroyuki
    Kato, Takefumi
    Watanabe, Tsuyoshi
    Hayashi, Masatoshi
    Shioura, Tomone
    Kanayama, Yasuhide
    Funahashi, Koji
    Asai, Shuji
    Yoshioka, Yutaka
    Terabe, Kenya
    Takemoto, Toki
    Asai, Nobuyuki
    Ishiguro, Naoki
    CLINICAL RHEUMATOLOGY, 2016, 35 (01) : 219 - 225
  • [43] Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients
    Toshihisa Kojima
    Nobunori Takahashi
    Atsushi Kaneko
    Daihei Kida
    Yuji Hirano
    Takayoshi Fujibayashi
    Yuichiro Yabe
    Hideki Takagi
    Takeshi Oguchi
    Hiroyuki Miyake
    Takefumi Kato
    Tsuyoshi Watanabe
    Masatoshi Hayashi
    Tomone Shioura
    Yasuhide Kanayama
    Koji Funahashi
    Shuji Asai
    Yutaka Yoshioka
    Kenya Terabe
    Toki Takemoto
    Nobuyuki Asai
    Naoki Ishiguro
    Clinical Rheumatology, 2016, 35 : 219 - 225
  • [44] How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors
    Gaspar Ramos, Jorge
    Miranda, Dafhne
    Cruz-Dominguez, Pilar
    Javier Jara, Luis
    Saavedra, Miguel A.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [45] Dysregulation of membrane-bound tumor necrosis factor-alpha and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: Low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load
    Hestdal, K
    Aukrust, P
    Muller, F
    Lien, E
    Bjerkeli, V
    Espevik, T
    Froland, SS
    BLOOD, 1997, 90 (07) : 2670 - 2679
  • [46] THE RISK OF INFECTION BY TUMOR NECROSIS FACTOR INHIBITORS AND ITS ASSOCIATED FACTORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULT FROM KOREAN NATIONAL HEALTH INSURANCE DATA
    Koo, Bon San
    Lim, Yu-Cheol
    Lee, Min-Young
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Oh, In-Sun
    Shin, Ju-Young
    Lee, Eui-Kyung
    Kim, Tae-Hwan
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 869 - 870
  • [47] Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study
    Chen, Sarah K.
    Liao, Katherine P.
    Liu, Jun
    Kim, Seoyoung C.
    ARTHRITIS CARE & RESEARCH, 2020, 72 (01) : 9 - 17
  • [48] Risk of Primary Gastrointestinal Lymphoma in Patients With Inflammatory Conditions Exposed to Tumor Necrosis Factor Alpha Inhibitors and Immunomodulators: A Case-Control Study (vol 6, otae010, 2024)
    Braga-Neto, Manuel B.
    Nasser, Jason
    Wang, Xiao Jing
    Harmsen, William Scott
    Raffals, Laura E.
    Camilleri, Michael
    Chedid, Victor
    CROHNS & COLITIS 360, 2024, 6 (02)
  • [49] Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis
    So, Min Wook
    Kim, A-Ran
    Lee, Seung-Geun
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 881 - 895
  • [50] ANTI-TUMOR NECROSIS FACTOR THERAPY IS NOT ASSOCIATED WITH POST-OPERATIVE INFECTION: RESULTS FROM PROSPECTIVE COHORT OF ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS UNDERGOING SURGERY TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE INFECTION I (PUCCINI)
    Cohen, Benjamin L.
    Fleshner, Phillip
    Kane, Sunanda V.
    Herfarth, Hans H.
    Palekar, Nicole
    Farraye, Francis A.
    Leighton, Jonathan A.
    Katz, Jeffry
    Cohen, Russell D.
    Gerich, Mark E.
    Cross, Raymond K.
    Higgins, Peter D.
    Tinsley, Andrew
    Glover, Sarah C.
    Siegel, Corey A.
    Bohl, Jaime L.
    Iskandar, Heba
    Raymond, Samantha
    Huang, Ruiqi
    Suarez-Farinas, Mayte
    Sands, Bruce E.
    GASTROENTEROLOGY, 2019, 156 (06) : S80 - S80
12345